76.82 0.00 (0.00%)
After hours: 4:58PM EDT
|Bid||66.12 x 100|
|Ask||79.60 x 100|
|Day's range||75.30 - 78.35|
|52-week range||67.00 - 91.03|
|PE ratio (TTM)||10.30|
|Dividend & yield||0.00 (0.00%)|
|1y target est||N/A|
Hospitals will most likely see rising bad debt in 2018 after President Trump ended Obamacare's cost-sharing reductions.
The large for-profit insurers and hospitals will find ways to grow, whether or not the GOP's health-reform bill is passed this summer.
Cramer spoke one day after health-care stocks posted sharp gains after the Senate released its health bill.
The Republican bill threads the needle on the industry's concerns, by funding insurance subsidies near-term, while pushing out deep cuts to Medicaid.
The news comes at a time when health-care companies and hospitals are seesawing on President Donald Trump's every word about the industry.
This analyst says the hospital stocks' rally might not continue, even with Obamacare remaining intact.
Obamacare repeal and failed insurance mergers have dominated health care headlines, but there are some surprise stock winners that could emerge.
NEW YORK/LONDON, Nov 9 (Reuters) - Pharmaceutical and biotechnology shares soared on Wednesday as Republican Donald Trump's U.S. presidential election calmed investor fears of tough action on drug pricing that has pressured the sector for more than a year. Hospital shares tumbled as a Republican sweep of Congress raised prospects for a rollback of the Affordable Care Act (ACA), which expanded the number of patients in government health plans. Fears of a win by Hillary Clinton and Democrats gaining power in Congress had clouded the outlook for biotech and pharma shares and contributed to general underperformance for the U.S. healthcare sector this year.
Donald Trump has promised that one of the first things he will do as president is to repeal Obamacare. What would that look like?